Germany to invest billions of Euros in healthcare research

Germany has allocated more than €5.5bn (US$8bn) in federal grants to support healthcare research over the next four years. The country trails only the US in biopharmaceutical production, and this new programme will provide a boost to bringing research results rapidly to market, according to Germany Trade & Invest, the foreign trade and inward investment promotion agency that advises foreign companies looking to expand their business activities in the German market.

‘Germany is already known as an established player in the pharmaceutical industry. A wealth of innovative small and medium enterprises and excellent opportunities for research partnerships are helping the country maintain its edge,’ said Gabriel Flemming, medical biotechnology expert at Germany Trade & Invest in Berlin.

For years, the combination of policymaking, research and development, venture capital and industry initiatives have taken Germany's industry in a fresh direction. With an emphasis on biotechnology, the industry is becoming increasingly sustainable while finding innovative ways to tackle public health challenges.

‘Germany is especially making progress in the field of personalised medicine,’ continued Flemming. ‘Foreign companies and venture capitalists are drawn to German biotechnology clusters, as diagnostics firms are working closely with the biopharmaceutical industry to create innovation hotbeds across the country.’